Company profile
Vascular Experts | Reprogo
Here in ReproGO, we are world leaders in vascular stem cell biology. Your one stop solution for matched patient-specific cells.
Updated 06 Jun 2026 16:52
Financial period: 1 Apr 2024 to 31 Mar 2025
Reference milestones and recent Companies House filing stream events.
Next confirmation statement due date
Next accounts due date
Last confirmation statement made up date
Last accounts made up date
Company registered at Companies House
ReproGo develops technology that produces stem-cells for specific patients.
The company is a start-up focusing on developing and marketing of inducible pluripotent stem cells. In the first instance these will be for sale to R&D clients, e.g. in drug screening assays. In the future there is the potential to develop for therapeutic use
The company attracted a total of £50K of support for customer discovery ant team formation from Innovate UK through ICURe, and was invited to apply for the aid for start-ups programme for ICURe companies. This was successfully awarded and company incorporated in 2020, although commencement of the award was delayed due to the coronavirus pandemic
1 Sep 2025 to 31 Aug 2026
ReproGo is developing **VasIntel**, an AI-powered platform that simulates how real human tissues respond to genes, compounds, and disease triggers --- enabling scientists and pharmaceutical companies to reduce lab burden, de-risk decisions, and accelerate discovery. Unlike traditional approaches that rely on animal testing or generic models, VasIntel is t...
1 Mar 2021 to 30 Nov 2022
Since their advent in 2006, induced pluripotent stem cells (iPSCs) have demonstrated a huge potential for disease modelling, drug discovery and regenerative medicine. Through genetic modification, adult cells already differentiated to specific tissues are reverted back, or 'reprogrammed' to an embryonic-like state, creating cells with self-renewal propert...
